Beam Therapeutics Inc. — FY2022 Form 10-K Summary
Business context and reporting period
Beam Therapeutics is an early-stage biotechnology company developing precision genetic medicines based primarily on base-editing technology, with delivery platforms spanning ex vivo cell therapy and in vivo lipid nanoparticles. The filing covers the fiscal year ended December 31, 2022; it is an annual filing rather than a standalone fourth-quarter report.
- Lead clinical programs: BEAM-101 for sickle cell disease and BEAM-201 for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma.
- Development candidates: BEAM-301 for glycogen storage disease 1a and BEAM-302 for alpha-1 antitrypsin deficiency.
- Beam had 507 full-time employees at year-end, including 301 in research and development, 34 in clinical activities, 46 in technical operations, 35 in quality, and 91 in general and administrative roles.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| License and collaboration revenue | $60.9 million | $51.8 million | +$9.1 million |
| Research and development expense | $311.6 million | $387.1 million | -$75.5 million |
| General and administrative expense | $87.8 million | $57.2 million | +$30.6 million |
| Loss from operations | $(338.5) million | $(392.5) million | Improved by $54.0 million |
| Net loss | $(289.1) million | $(370.6) million | Improved by $81.6 million |
| Net loss per share | $(4.13) | $(5.77) | Improved |
| Cash flow from operations | $22.5 million provided | $66.3 million used | Improved by $88.8 million |
| Capital expenditures | $49.0 million | $46.8 million | +$2.1 million |
| Cash, cash equivalents and marketable securities | $1.078 billion | $965.6 million | +$112.5 million |
Revenue remained collaboration-driven; Beam reported no product sales and expects no product-sales revenue in the near term. Approximate operating margin was negative 556% and net margin was negative 475%, reflecting the company’s development-stage profile.
- Year-end cash and cash equivalents were $232.8 million and marketable securities were $845.4 million. Including restricted cash, cash, cash equivalents and restricted cash totaled $245.5 million.
- Total liabilities were $608.2 million, including $3.0 million of equipment financing liabilities, $179.0 million of operating lease liabilities, $30.8 million of derivative and contingent consideration liabilities, and $338.2 million of deferred revenue.
- Operating cash flow benefited materially from collection of the $300.0 million Pfizer upfront payment and was not representative of recurring operating performance.
- Stock-based compensation increased to $84.3 million from $43.6 million in 2021.
Material changes versus the prior comparable period
- Revenue increased primarily because 2022 included revenue from Pfizer, Apellis, Orbital and Verve collaborations. Pfizer revenue recognized in 2022 was $48.2 million; remaining Pfizer deferred revenue was $251.8 million at year-end.
- Research and development expense declined because 2021 included a $155.0 million in-process research and development charge related to the Guide acquisition. This was partly offset by higher external development, employee, facility, IT and stock-based compensation costs.
- General and administrative expense rose because of higher personnel and stock-based compensation costs and a $3.4 million accrual related to a research-institution dispute.
- Other income increased to $78.3 million from $21.8 million, including $23.9 million from the decrease in the fair value of Harvard and Broad success-payment liabilities, $20.2 million from equity investment fair-value changes, $18.9 million from the decrease in Guide contingent consideration liabilities, and $15.3 million of interest and other income.
- Beam recognized a $25.5 million loss from its equity-method investment in Orbital, reducing the investment’s carrying value to zero.
- The company raised approximately $108.3 million net through equity offerings in 2022. Year-end common shares outstanding were 71.3 million, compared with 68.4 million at December 31, 2021.
- Construction of the 100,000-square-foot North Carolina manufacturing facility was substantially completed in 2022. The facility became operational in the first quarter of 2023, with cGMP operations expected to begin in late 2023.
Guidance, outlook, risks and unusual items
- Management expects existing cash, cash equivalents and marketable securities to fund current and planned operating expenses and capital expenditures for at least the next 12 months from the financial-statement issuance date. Management also states that additional financing will be needed to support longer-term operations and growth.
- Beam expected to complete the BEAM-101 sentinel cohort and begin expansion enrollment in 2023, with data from multiple patients expected in 2024.
- The FDA cleared the BEAM-201 IND in December 2022; Beam expected to dose the first patient by mid-2023.
- Beam initiated IND-enabling studies for BEAM-301 and planned to submit a regulatory application by late 2023 or early 2024. It planned an application for BEAM-302 in early 2024.
- Key risks include the lack of clinically validated base-editing therapies, uncertain clinical efficacy and safety, off-target or unintended edits, permanent genetic changes, delivery and manufacturing challenges, regulatory delays, patient enrollment constraints, competition, intellectual-property disputes, reliance on third parties, and the need for additional capital.
- The company disclosed an unresolved dispute with a research institution alleging breach of confidentiality, trade-secret misappropriation and related claims involving BEAM-102 and BEAM-302. Beam accrued $3.4 million, but the settlement proposal was rejected; no complaint had been filed, and the ultimate outcome could differ materially from the accrued amount.
- Remaining potential obligations include up to $90.0 million each in additional Harvard and Broad success payments, up to $100.0 million in Guide technology milestones and $220.0 million in Guide product milestones, plus other licensing, royalty and milestone obligations.
- Beam reported effective disclosure controls and internal control over financial reporting, with an unqualified audit opinion from Deloitte & Touche LLP.
Important facts for investors to verify
- Whether the reported cash runway remains adequate after 2022, considering clinical-trial expansion, manufacturing costs and continuing operating losses.
- Progress, safety findings, enrollment and efficacy data for BEAM-101 and BEAM-201.
- Timing and regulatory status of BEAM-301 and BEAM-302 IND submissions.
- Development of the North Carolina facility, including the start and scalability of cGMP operations.
- Remaining collaboration deferred revenue, particularly the Pfizer and Apellis obligations and the timing of future revenue recognition.
- Status and potential exposure from the research-institution dispute and intellectual-property proceedings affecting base-editing and CRISPR technologies.
- Future equity issuance, dilution and contingent stock payments under the ATM facility, Guide acquisition and license agreements.